Cargando…
PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431511/ http://dx.doi.org/10.1097/01.HS9.0000850824.39215.bd |
| _version_ | 1784780075381555200 |
|---|---|
| author | Faulkner, L. Garg, M. Suresh, C. |
| author_facet | Faulkner, L. Garg, M. Suresh, C. |
| author_sort | Faulkner, L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431511 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94315112022-08-31 PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT Faulkner, L. Garg, M. Suresh, C. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431511/ http://dx.doi.org/10.1097/01.HS9.0000850824.39215.bd Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Faulkner, L. Garg, M. Suresh, C. PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT |
| title | PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT |
| title_full | PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT |
| title_fullStr | PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT |
| title_full_unstemmed | PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT |
| title_short | PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT |
| title_sort | pb1998: weekly opposed to bi-weekly bortezomib as part of induction chemotherapy in newly diagnosed multiple myeloma is better tolerated and equally efficient: real-world data from a retrospective audit |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431511/ http://dx.doi.org/10.1097/01.HS9.0000850824.39215.bd |
| work_keys_str_mv | AT faulknerl pb1998weeklyopposedtobiweeklybortezomibaspartofinductionchemotherapyinnewlydiagnosedmultiplemyelomaisbettertoleratedandequallyefficientrealworlddatafromaretrospectiveaudit AT gargm pb1998weeklyopposedtobiweeklybortezomibaspartofinductionchemotherapyinnewlydiagnosedmultiplemyelomaisbettertoleratedandequallyefficientrealworlddatafromaretrospectiveaudit AT sureshc pb1998weeklyopposedtobiweeklybortezomibaspartofinductionchemotherapyinnewlydiagnosedmultiplemyelomaisbettertoleratedandequallyefficientrealworlddatafromaretrospectiveaudit |